[{"address1": "7707 Gateway Boulevard", "address2": "Suite 140", "city": "Newark", "state": "CA", "zip": "94560", "country": "United States", "phone": "510 474 0170", "website": "https://www.protagonist-inc.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.", "fullTimeEmployees": 128, "companyOfficers": [{"maxAge": 1, "name": "Dr. Dinesh V. Patel Ph.D.", "age": 67, "title": "CEO, President, Secretary & Director", "yearBorn": 1957, "fiscalYear": 2024, "totalPay": 1366917, "exercisedValue": 41362, "unexercisedValue": 37923696}, {"maxAge": 1, "name": "Mr. Asif  Ali", "age": 50, "title": "Executive VP & CFO", "yearBorn": 1974, "fiscalYear": 2024, "totalPay": 805042, "exercisedValue": 586039, "unexercisedValue": 1554023}, {"maxAge": 1, "name": "Dr. Suneel K. Gupta Ph.D.", "age": 66, "title": "Executive Vice President of Clinical Development", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 896847, "exercisedValue": 7759965, "unexercisedValue": 2687758}, {"maxAge": 1, "name": "Dr. Arturo M. Molina FACP, M.D., M.S.", "age": 65, "title": "Chief Medical Officer", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 956912, "exercisedValue": 1160875, "unexercisedValue": 1642455}, {"maxAge": 1, "name": "Mr. Mohammad  Masjedizadeh Ph.D.", "title": "Executive VP & CTO", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Newman  Yeilding", "title": "Executive VP, Chief Scientific Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew M. Gosling J.D.", "age": 53, "title": "Executive VP and Chief Legal & Business Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Carena  Spivey", "title": "Senior VP & Chief Human Resources Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Ashok  Bhandari Ph.D.", "age": 60, "title": "EVP & Chief Discovery Officer", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Carter J. King", "age": 53, "title": "Executive Vice President of Business Development", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 7, "overallRisk": 8, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 88.84, "open": 88.78, "dayLow": 87.47, "dayHigh": 89.61, "regularMarketPreviousClose": 88.84, "regularMarketOpen": 88.78, "regularMarketDayLow": 87.47, "regularMarketDayHigh": 89.61, "payoutRatio": 0.0, "beta": 2.191, "trailingPE": 134.51514, "forwardPE": 83.65528, "volume": 380284, "regularMarketVolume": 380284, "averageVolume": 1167565, "averageVolume10days": 944790, "averageDailyVolume10Day": 944790, "bid": 65.52, "ask": 113.28, "bidSize": 2, "askSize": 2, "marketCap": 5550140416, "fiftyTwoWeekLow": 33.7, "fiftyTwoWeekHigh": 96.54, "allTimeHigh": 96.54, "allTimeLow": 4.47, "priceToSalesTrailing12Months": 26.528152, "fiftyDayAverage": 83.9853, "twoHundredDayAverage": 61.3308, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 4984772608, "profitMargins": 0.21943001, "floatShares": 49893128, "sharesOutstanding": 62515666, "sharesShort": 6539025, "sharesShortPriorMonth": 5582326, "sharesShortPreviousMonthDate": 1763078400, "dateShortInterest": 1765756800, "sharesPercentSharesOut": 0.1046, "heldPercentInsiders": 0.010089999, "heldPercentInstitutions": 1.16037, "shortRatio": 6.62, "shortPercentOfFloat": 0.12529999, "impliedSharesOutstanding": 62515666, "bookValue": 10.336, "priceToBook": 8.5893955, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": 45909000, "trailingEps": 0.66, "forwardEps": 1.06126, "enterpriseToRevenue": 23.826, "enterpriseToEbitda": 248.865, "52WeekChange": 1.3053753, "SandP52WeekChange": 0.17318606, "quoteType": "EQUITY", "currentPrice": 88.78, "targetHighPrice": 115.0, "targetLowPrice": 65.0, "targetMeanPrice": 94.5, "targetMedianPrice": 94.0, "recommendationMean": 1.41667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 576116992, "totalCashPerShare": 9.216, "ebitda": 20030000, "totalDebt": 10749000, "quickRatio": 12.938, "currentRatio": 13.048, "totalRevenue": 209216992, "debtToEquity": 1.665, "revenuePerShare": 3.313, "returnOnAssets": 0.0182, "returnOnEquity": 0.077989995, "grossProfits": 209216992, "freeCashflow": 53095000, "operatingCashflow": 65468000, "revenueGrowth": 0.008, "grossMargins": 1.0, "ebitdaMargins": 0.095740005, "operatingMargins": -9.85166, "financialCurrency": "USD", "symbol": "PTGX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "shortName": "Protagonist Therapeutics, Inc.", "earningsTimestampEnd": 1762462800, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": 0.66, "epsForward": 1.06126, "epsCurrentYear": -1.87111, "priceEpsCurrentYear": -47.447773, "fiftyDayAverageChange": 4.7947006, "fiftyDayAverageChangePercent": 0.05708976, "twoHundredDayAverageChange": 27.4492, "twoHundredDayAverageChangePercent": 0.4475598, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "cryptoTradeable": false, "marketState": "CLOSED", "longName": "Protagonist Therapeutics, Inc.", "regularMarketChangePercent": -0.0675344, "regularMarketPrice": 88.78, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1470922200000, "postMarketChangePercent": 0.0, "postMarketPrice": 88.78, "postMarketChange": 0.0, "regularMarketChange": -0.0599976, "regularMarketDayRange": "87.47 - 89.61", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1167565, "fiftyTwoWeekLowChange": 55.079998, "fiftyTwoWeekLowChangePercent": 1.6344212, "fiftyTwoWeekRange": "33.7 - 96.54", "fiftyTwoWeekHighChange": -7.760002, "fiftyTwoWeekHighChangePercent": -0.08038121, "fiftyTwoWeekChangePercent": 130.53754, "earningsTimestampStart": 1762462800, "corporateActions": [], "postMarketTime": 1766789268, "regularMarketTime": 1766782800, "exchange": "NGM", "messageBoardId": "finmb_129263324", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "displayName": "Protagonist Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-27"}]